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A B S T R A C T
Six series of semisynthetic lipophilic glycopeptide antibiotic derivatives were evaluated for in vitro activ-
ity against influenza A and B viruses. The new teicoplanin pseudoaglycon-derived lipoglycopeptides were
prepared by coupling one or two side chains to the N-terminus of the glycopeptide core, using various con-
jugation methods. Three series of derivatives bearing two lipophilic groups were synthesized by attaching
bis-alkylthio maleimides directly or through linkers of different lengths to the glycopeptide. Access to the
fourth and fifth series of compounds was achieved by click chemistry, introducing single alkyl/aryl chains di-
rectly or through a tetraethylene glycol linker to the same position. A sixth group of semisynthetic derivatives
was obtained by sulfonylation of the N-terminus. Of the 42 lipophilic teicoplanin pseudoaglycon derivatives
tested, about half showed broad activity against influenza A and B viruses, with some of them having reason-
able or no cytotoxicity. Minor differences in the side chain length as well as lipophilicity appeared to have
significant impact on antiviral activity and cytotoxicity. Several lipoglycopeptides were also found to be ac-
tive against human coronavirus.
© 2018.
1. Introduction
Human influenza A and B viruses cause the annual influenza epi-
demics and sporadic pandemics associated with high fatality rate [1].
The viral envelope contains two glycoproteins with a crucial role in
virus replication. The hemagglutinin (HA) is responsible for initial at-
tachment of the virus to sialylated cell surface glycans, and fusion
of the viral and endosomal membranes after endocytosis of the virus
particle [2]. The influenza virus neuraminidase (NA) catalyzes re
Abbreviations: DCM, dichloromethane; DMF, dimethylformamide; CPE, cyto-
pathic effect; Et3N, triethylamine; Galp, galactopyranoside; HA, hemagglutinin;
HIV, human immunodeficiency virus; logP, logarithm of the partition coeffi-
cient; MCC, minimum cytotoxic concentration; MDCK, Madin−Darby Canine
Kidney; M2, Matrix-2; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; NA, neuraminidase; Ph,
phenyl; PMB, p-methoxybenzyl; SARS-CoV, severe acute respiratory syndrome
coronavirus; SI, selectivity index; SEM, standard error of the mean; TEG, tetraeth-
ylene glycol; TLC, thin layer chromatography; tosyl, p-toluenesulfonyl
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lease of newly formed virions at the end of the viral life cycle. Cur-
rently available influenza virus blockers are the NA inhibitors os-
eltamivir and zanamivir, and the M2 ion channel blockers amanta-
dine and rimantadine [3]. The latter two are rarely used nowadays
because of global viral resistance against them [4]. The increasing
awareness of potential oseltamivir resistance [5,6] advocates the need
for new anti-influenza medications. Clinical trials are ongoing for a
few HA-targeting approaches, i.e. the fusion inhibitor arbidol and di-
verse broadly neutralizing anti-HA antibodies [3]. In addition, the pos-
sibility to target a host factor involved in HA functioning is tested with
the HA maturation inhibitor nitazoxanide and a receptor-destroying
sialidase enzyme, besides various concepts in the preclinical stage [7].
Antiviral drugs are also required for pandemic preparedness
against zoonotic and highly virulent influenza viruses [8]. In this
context, antiviral glycopeptide analogues seem particularly relevant
since they often display broad activity against influenza plus some
other emerging viruses. Derivatives of teicoplanin or related antibi-
otics were reported to inhibit, among others, influenza virus [9]; coro-
naviruses [10] including SARS-CoV (severe acute respiratory syn-
drome coronavirus) [11]; Ebola pseudovirus [12]; HIV [13]; or he-
patitis C virus [14]. Our focus of the last years was to investigate the
structure-activity relationship and mechanism of action for influenza
virus. We reported lipophilic derivatives of ristocetin aglycon modi
https://doi.org/10.1016/j.ejmech.2018.08.058
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fied on the N-terminal part of the molecule, which proved to be strong
inhibitors of influenza virus replication in cell culture [15]. Mecha-
nistic studies with the lead compound demonstrated that it interferes
with influenza virus endocytosis [16]. Its favorable selectivity index
encouraged us to prepare a series of analogues to gain further insight
into structure activity relationships [17,18]. The outstanding antiviral
properties were lost in analogues containing teicoplanin aglycon or
pseudoaglycon, meaning that minor structural differences between the
aglycon of teicoplanin and that of ristocetin, have major impact on an-
tiviral activity [19].
Next, we found that a special lipophilic modification of teicoplanin
pseudoaglycon also resulted in derivatives with high anti-influenza
virus activity [20]. These derivatives contain a sugar unit carrying two
n-octyl chains, and this lipophilic auxiliary is attached to teicoplanin
pseudoaglycon through a tetraethylene glycol chain and a triazole ring
(1a and 1b, Fig. 1). Although the antiviral mode of action of 1a and
1b remains to be elucidated, we observed that these dually octylated
teicoplanin pseudoaglycon derivatives inhibit influenza virus-induced
hemagglutination, suggesting that they interfere with the binding in-
teraction between the viral HA and sialylated host cell receptors. We
also found that the lipophilic side chains in these molecules are essen-
tial for anti-influenza virus activity, since changing these octyl chains
to methyl groups (1c) completely abolished the antiviral effect [20].
Unfortunately, the strong activity of 1a and 1b was accompanied by
high cytotoxicity, while the inactive and less amphiphilic 1c was only
moderately toxic.
Surprisingly, we recently found that teicoplanin pseudoaglycon
achieves anti-influenza virus properties by a simple lipophilic modifi
cation based on the well-known azide-alkyne cycloaddition click re-
action (2a-j) [21]. The activity oddly correlated to the structure, since
it disappeared and then reappeared by increasing the length of the
lipophilic alkyl chains. Changes in cytotoxicity, however, were more
consistent and indicated that the addition of longer alkyl substituents
resulted in higher cytotoxicity. Although compounds 2a and 2d
showed excellent inhibitory activity against influenza virus, their se-
lectivity indices were unfavorable [21]. Noteworthy, some of these
derivatives with amphiphilic, bulky substituents (2i, 2j) displayed
anti-influenza virus activity without significant cytotoxicity, despite
their high calculated logP values.
With the aim of achieving derivatives with more favorable biolog-
ical properties, we decided to carry out a systematic structure-activity
relationship analysis of teicoplanin pseudoaglycon derivatives resem-
bling 1a, 1b, or e.g. 2d. A simple conjugation method for protein and
peptide modification was reported [22], involving rapid and clean re-
action of 3,4-dibromomaleimides and thiols, and giving bis-alkylthio
maleimides in high yields through an addition-elimination mecha-
nism. We envisioned the application of maleimide chemistry in com-
bination with azide-alkyne click chemistry, to produce three sets of te-
icoplanin derivatives equipped with two lipophilic substituents simi-
larly as in 1a and 1b. (In the Discussion, these derivatives are denoted
as Series 1–3). Compounds 2a-j are referred to in the SAR analysis as
Series 4. Two further sets of derivatives (Series 5 and 6) comparable
to 2a-g, which contain only one lipophilic alkyl chain, were prepared
by azide-alkyne 1,3-dipolar cycloaddition reaction and by N-sulfony-
lation. Here we describe the synthesis and antiviral investigation of
these compounds.
Fig. 1. Structure of previously synthesized teicoplanin derivatives. Compounds 1a, 1b, 2a and 2d showed promising anti-influenza virus activity; 1c, 2b, and 2c were inactive; and
2e showed modest activity [20,21]. (PMB = p-methoxybenzyl).
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2. Results and discussion
Chemistry. The first group of derivatives (12–18) was prepared
by synthesizing various bis-alkylthio maleimides 4a-10a from 3,4-di-
bromomaleimide 3, followed by subsequent ethoxycarbonylation of
the maleimide NH group [23] making compounds 4b-10b suitable
for conjugation to the N-terminus of teicoplanin pseudoaglycon 11
(Scheme 1). Although we have described this path earlier [24] for
the synthesis of compounds 4, 7, 8, 10, 12, 15, 16, 18, this time we
also prepared the bis-n-butylthio and bis-n-hexylthio maleimide deriv-
atives (5 and 6) for the sake of the systematic approach in this study.
We also prepared the asymmetrically substituted maleimide variant 9
that has an n-propyl and n-dodecyl function.
The second series of derivatives contains similar maleimide-de-
rived side chains as the previous group, but these are attached through
a triazole linker to the glycopeptide core, in order to increase the dis-
tance of the lipophilic chains from the pseudoaglycon. In this synthetic
procedure we prepared N-propargyl maleimides 19–24 by reaction of
the corresponding N-ethoxycarbonyl maleimides (4b-8b, 10b) with
propargylamine. Finally, an azide-alkyne click reaction was carried
out between azido teicoplanin pseudoaglycon 25 [9] and maleimides
19–24, yielding final products 26–31 (Scheme 2).
The third group of derivatives carrying maleimide substituents dif-
fers from the previous one in the structure of the linker, which in this
case contains a tetraethylene glycol segment besides the triazole ring
as in compounds 1a and 1b. By introduction of the tetraethylene gly-
col fragment, the overall lipophilicity of the compounds is reduced,
while the crucial lipophilic substituents are still incorporated in the
structure. This linker modification proved to have a substantial effect
on the biological profile of the molecules (see below).
The compounds suitable for this type of modification (33–39)
were prepared by the simple reaction of N-ethoxycarbonyl
maleimides 4b-8b, 10b, 32b and triethylene glycol 2-aminoethyl
propargyl ether. Subsequent click reaction with azido teicoplanin
pseudoaglycon 25 gave glycopeptides 40–46 (Scheme 3).
The fourth type of modification we describe here was based on
our previous results mentioned above. Although compounds 2a and
2d possessing single, relatively long alkyl chains were highly active
against influenza virus, they also displayed considerable cytotoxicity
[21]. (For the sake of clarity, these compounds are listed as a separate
series, i.e. Series 4 in Table 1. The structures can be found in Fig. 1.)
We speculated that this high cytotoxicity might be related to a
combination of two factors, the first being high lipophilicity of the
side chains in contrast to the hydrophilic pseudoaglycon part, which
may cause a membrane-disrupting effect. This might be enhanced by
the simple structure of the alkyl chains, which could facilitate inser-
tion of these molecules into biological membranes. In our previous
work [21] we attached two very bulky substituents (a perbenzylated
disaccharide and a calix[4]arene carrying tert-butyl-substituents) to
the same pseudoaglycon (2i and 2j). Calculated logP values for these
compounds indicated higher lipophilicity than e.g. the n-hexadecyl or
n-octyl derivatives 2a and 2d. These derivatives did not produce pro-
found cytotoxic effect, supporting our hypothesis that cytotoxicity is
determined by the combination of the lipophilicity and bulkiness of
the substituents. It needs to be mentioned here, that in the A2 com-
ponents of teicoplanin the ß-D-glucosamine on the D-ring is N-acy-
lated by similarly simple acyl chains, yet these compounds seem to
be harmless to mammalian cells. Therefore, the overall lipophilicity of
the molecules may also influence cytotoxicity.
Since the introduction of alkyl chains proved to be promising in
terms of antiviral activity, we decided to insert the tetraethylene gly-
col linker between the core and these substituents, in order to de-
crease lipophilicity as in the case of maleimide derivatives, which
again caused a significant change in biological properties.
Scheme 1. Synthesis of maleimide derivatives 12–18 (Series 1) with double lipophilic tails by direct coupling of 4–10 to teicoplanin pseudoaglycon 11.
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Scheme 2. Conjugation of the bis-alkylthio maleimide derivatives 19–24 to azido te-
icoplanin pseudoaglycon 25 through a triazole moiety (Series 2).
Scheme 3. Conjugation of bis-alkylthio maleimide derivatives equipped with an
N-TEG-propargyl moiety (33–39) to azido teicoplanin pseudoaglycon 25 gave Series 3
(40–46).
First, the mono-azido derivative of tetraethylene glycol 47 was uti-
lized in a click reaction with alkyl propargyl ethers 48–51, yielding tri-
azole derivatives 52–55. These were O-alkylated with propargyl bro-
mide to provide compounds 56–59, which were used in the last step in
a CuAAC reaction with azido teicoplanin pseudoaglycon 25 to obtain
derivatives 60–63 (Scheme 4).
Finally, by the reaction of teicoplanin pseudoaglycon with dif-
ferent sulfonyl chlorides 64–71 we prepared sulfonamide derivatives
(72–79) (Scheme 5). This type of derivatization was attractive mainly
because of its simplicity and high stability of the sulfonamide bond.
Despite this, to our knowledge no one has thus far reported this type
of derivatives of teicoplanin or related glycopeptides.
Biological evaluation. The anti-influenza virus activity was deter-
mined in Madin-Darby canine kidney (MDCK) cells using a reported
cytopathic effect (CPE) reduction method, in which CPE is assessed
by microscopy plus formazan-based cell viability assay [25]. In paral-
lel, cytotoxicity was determined in mock-infected cells. Table 1 sum
marizes the data for three human influenza A strains (including an A/
H1N1 2009 pandemic strain) plus one influenza B strain.
Series 1, maleimide derivatives 12–18, showed variable activity
against the four influenza virus strains tested, but neither of them
proved as potent as compound 1a. Only compounds 17 and 18 dis-
played quite consistent activity against the four strains. Curiously
enough, neither the double n-propyl nor the double n-dodecyl substi-
tuted maleimide moieties yielded active compounds, while the combi-
nation of n-propyl and n-dodecyl chains (compound 17) led to notable
activity. The fair activity of compound 18 carrying a double galactose
substituted maleimide was accompanied by modest selectivity with an
SI of 5 [selectivity index (SI): ratio of MCC to average EC50]. This in-
dicated the need for structural modification in order to reduce the cy-
totoxicity.
Series 2 (26–31) containing the triazole linker was, overall, more
successful against influenza virus with somewhat lower cytotoxicity
than the first series. Namely, antiviral activity was seen in the case of
compounds 27, 28 and 29 which contain double n-butyl, n-hexyl and
n-octyl chains, respectively. The presence of the linker highly altered
the behavior of these compounds, since the analogous derivatives in
the previous series (i.e. no triazole linker) with the same alkyl chain
lengths were inactive. 29 displayed robust antiviral activity and a fa-
vorable SI of 10, whereas 27 and in particular 28 still had poor selec-
tivity. 30 with the double n-dodecyl moiety remained inactive, but be-
came less cytotoxic, which was a general finding in Series 2. Sadly,
the double galactose substituted derivative lost its activity on introduc-
tion of the triazole linker.
The biological results for Series 3 (40–46) demonstrated that by
introducing the tetraethylene glycol linker, cytotoxicity was generally
reduced, while the anti-influenza virus activity was retained in the
n-butyl (41) and n-hexyl (42) derivatives, and even increased in the
n-octyl (43) analogue. Since the tetraethylene glycol element seemed
beneficial, we also prepared a derivative with double tetraethylene
glycol side chains (46), but this modification did not yield an ac-
tive compound, probably because it misses the lipophilic moiety that
proved to be essential for anti-influenza virus activity (see conclu-
sions). Surprisingly, despite the lack of lipophilic moieties, compound
46 proved to be highly cytotoxic. Ultimately, 41 stood out as the most
promising compound in this group, with very low cytotoxicity and ro-
bust activity against all tested strains, yielding a nice SI of 16.
The activities of triazole derivatives (2a-j) in Series 4 have already
been published [21] elsewhere. These data are shown again, consid-
ering the systematic approach in our present report and the struc-
tural analogy to some of the compounds in this work. Surprisingly,
among the alkyl substituted compounds, only the n-hexadecyl (2a)
and n-octyl (2d) derivatives showed high activity, while the attach-
ment of n-dodecyl (2b) and n-decyl (2c) side chains led to inactive
compounds. However, all four derivatives had very high cytotoxic-
ity. 2e with a n-hexyl side chain and compounds with aromatic sub-
stituents (2f, 2g) were only mildly active with moderate cytotoxicity.
Interestingly, 2h and 2i (a perbenzylated lactose and a calix[4]arene
derivative) displayed moderately high activity which was accompa-
nied by only modest cytotoxicity, despite their very high calculated
logP values indicating much higher lipophilicity when compared to
2a. As stated above, the explanation could be that, although these mol-
ecules are very lipophilic, their bulky structures may lead to an inabil-
ity to disrupt cellular membranes as is the case for alkyl derivatives.
To further investigate how the tetraethylene glycol linker impacts
the cytotoxicity, we synthesized Series 5, derivatives 60–63, which
are analogous to the alkyl chain-containing triazole derivatives in Se
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Table 1
Activity in influenza virus-infected MDCKa cells.
Compound* Antiviral EC50
b Cytotoxicityc
A/H1N1 A/H1N1pdm A/H3N2 Influenza B
CPE MTS CPE MTS CPE MTS CPE MTS CC50 MCC
(μM)
1a 0.80 1.2 1.4 <0.80 1.8 1.2 >100# >100# 11 20
Series 1: Maleimide derivatives
12 (2x C3) >100 >100 1.8 2.0 >100 >100 >100 7.2 18 20
13 (2x C4) >100 >100 2.9 2.6 >100 >100 >100 >100 8.6 4
14 (2x C6) >100 >100 >100 >100 >100 >100 >100 >100 9.8 4
15 (2x C8) >100 >100 2.1 1.9 >100 >100 >100
# >100# 11 20
16 (2x C12) >100 >100 >100 >100 >100 >100 >100 >100 ≤1.1 ≤4.0
17 (C3, C12) >100 10 5.1 8.2 7.3 6.8 8.9 7.3 29 ≥20
18 (2 x Galp) >100 9.1 2.1 2.2 2.3 1.7 >100 4.2 26 20
Series 2: Maleimide derivatives with a triazole linker
26 (2x C3) >100 >100 >100 >100 >100 >100 >100
# >100# 22 20
27 (2x C4) 2.1 3.2 9.8 7.4 >100 4.9 2.5 3.5 28 20
28 (2x C6) 3.1 >100 4.0 2.9 1.9 1.9 2.3 2.7 12 ≥4
29 (2x C8) 9.2 12 4.4 3.4 8.9 6.3 6.7 7.2 49 73
30 (2x C12) >100 >100 >100 >100 >100 >100 >100
# >100# 75 100
31 (2 x Galp) >100 >100 >100 >100 >100 >100 >100# >100# 18 20
Series 3: Maleimide derivatives with a triazolyl TEG linker
40 (2x C3) >100 >100 >100 7.8 6.2 ≤7.8 >100
# >100# 38 20
41 (2x C4) 4.8 5.8 9.5 8.6 5.3 6.0 5.5 4.9 >100 100
42 (2x C6) 2.0 3.5 2.7 6.0 2.0 2.9 1.8 3.6 65 20
43 (2x C8) 1.3 2.0 ≤1.4 ≤0.80 0.92 ≤0.80 >20
# >20# 19 ≥4.0
44 (2x C12) >100 13 >100 2.8 >100 2.4 >100 >100 79 20
45 (2x TEG) >100 >100 >100 >100 >100 >100 >100 >100 3.0 4.0
46 (2 x Galp) >100 >100 >100 >100 >100 23 >100 42 ≥32 >100
Series 4: Triazole derivatives [21]
2a (C16) 1.6 1.8 1.8 1.8 ≤8.9 ≤1.6 1.8
# 1.3# 7.6 ≥4.0
2b (C12) >100 >100 >100 >100 >100 >100 >100
# >100# 2.3 9.3
2c (C10) >100 >100 >100 >100 >100 >100 >100
# >100# 3.7 4
2d (C8) >100 2.2 1.8 1.9 2.1 1.5 1.8
# 1.9# 13 ≥4.0
2e (C6) >100 >100 >100 >100 15 13 17
# 11# 53 ≥20
2f (Ph)l >100 >100 >100 >100 11 11 >100# >100# 41 ≥20
2g (α-Np) 11 11 11 4.4 15 8 15# 6.6# 47 20
2h (Galp) 52 47 45 43 39 24 39# 29# >100 ≥100
2i (lactose) >100 >100 8.9 7.3 8.9 20 6.6# 4.0# >100 ≥20
2j (calixarene) >100 43 8.9 6.7 >100 5.2 >100# 5.7# ≥58 ≥20
Series 5: Triazole derivatives with a TEG linker and single alkyl chains
60 (C4) >100 51 >100 47 >100 31 >100 28 >100 100
61 (C6) >100 >100 >100 >100 >100 >100 >100 >100 51 100
62 (C8) >100 >100 >100 >100 >100 >100 >100 >100 19 20
63 (C10) 1.6 1.5 1.8 1.8 1.6 1.3 >100 <0.80 ≥82 ≥20
Series 6: Sulfonamide derivatives
72 (toluyl) 9 11 30 32 41 19 11 12 >100 100
73 (Ph) 16 27 46 52 25 23 51 21 >100 100
74 (PhNHAc) >100 >100 >100 >100 >100 >100 >100 47 60 100
75 (biphenyl) 1.8 1.7 2.0 2.0 1.5 1.6 1.8 2.4 15 11
76 (dansyl) 4.9 7.0 6.3 5.9 8.3 2.3 6.7 5.3 52 20
77 (C6) 8.6 9.6 8.9 9.1 8.3 8.9 8.9 10.3 54 100
78 (C8) 1.9 2.5 >100 >100 2.0 2.4 4.0 >100 14 20
79 (C12) 0.4 0.8 >100 1.6 <0.8 <0.8 <0.8 <0.8 4.5 4.0
Zanamivir 0.041 0.19 1.9 30 20 3.2 0.0079 0.0062 >100 >100
Ribavirin 8.4 9.1 10 8.5 13 5.9 2.3 2.2 >100 >100
Amantadine >500 >500 >500 >500 11 1.9 >500 >500 >500 >500
Rimantadine >500 >500 >500 >500 0.20 0.17 >500 >500 >500 >500
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*Lipophilic substituents are specified in brackets.
aMDCK, Madin-Darby canine kidney cells.
bAntiviral activity expressed as the EC50, i.e. the compound concentration producing 50% inhibition of virus replication, as estimated by microscopic scoring of the cytopathic effect
(CPE) or by measuring cell viability in the formazan-based MTS assay. Influenza strains: A/PR/8/34 (A/H1N1); A/Virginia/ATCC3/2009 (A/H1N1pdm); A/HK/7/87 (A/H3N2); B/
Ned/537/05 or B/HK/5/72 (data marked with #).
cCytotoxicity expressed as the minimum cytotoxic concentration (MCC; compound concentration producing minimal changes in cell morphology, as estimated by microscopy) or
the 50% cytotoxic concentration (CC50; estimated by the MTS cell viability assay).
Data represent the means of two to five independent tests.
Scheme 4. Another variant (Series 5) of teicoplanin pseudoaglycon modification (60–63).
Scheme 5. Synthesis of sulfonamide derivatives (Series 6) of teicoplanin pseudoaglycon (72–79).
ries 4. We speculated that introduction of the linker would boost the
antiviral activity and reduce the cytotoxicity compared to the pub-
lished compounds. Indeed, compound 63 (an analogue of 2c) showed
excellent antiviral activity and reasonable cytotoxicity compared to 2c
which is highly cytotoxic and devoid of anti-influenza virus activity.
Interestingly, lowering the length of the alkyl chain (analogues 60–62)
did not yield effective compounds.
Also for the sulfonamide derivatives (Series 6), the size and type
of lipophilic substituents seemed to play an important role. The less
hydrophobic tosyl (72), benzenesulfonyl (73), and p-acetamido-ben-
zenesulfonyl (74) derivatives had rather low or no anti-influenza virus
activity and were also not cytotoxic. However, the more lipophilic
aryl substituted compounds, such as the biphenylsulfonyl
(75) and dansyl (76) derivatives, displayed good activity. Unfortu-
nately, they were also cytotoxic in the MDCK cells. The relation-
ship between alkyl chain length, cytotoxicity and antiviral activity was
very clear in case of alkylsulfonates 77–79. The hexanesulfonyl deriv-
ative (77) was the best compound showing moderate cytotoxicity and
very consistent anti-influenza virus activity. With growing alkyl chain
length (78, 79), the activity rapidly increased, but so did the cytotoxi-
city.
Inhibition of influenza HA- and NA-bearing lentiviral
pseudoparticles. We previously published the anti-influenza virus
mechanism of action of a lipophilic derivative of aglycoristocetin de-
noted SA-19 [16]. This compound proved to have nice activity in
an assay with green fluorescent protein (GFP)-expressing lentiviral
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pseudoparticles bearing influenza virus HA and NA. This was consis-
tent with other findings that SA-19 interferes with HA-mediated endo-
cytosis. We now used the same procedure for two of the most potent
teicoplanin pseudoaglycon derivatives (1a, 63). Strong and dose-de-
pendent inhibition was seen with all four control compounds (Fig. 3),
i.e. SA-19; chloroquine (an inhibitor of endosomal acidification); and
two aniline-based influenza fusion inhibitors (80, 81, Fig. 2) which
inhibit the conformational refolding of H1 HA at low endosomal pH
[26]. With 63, the inhibition of pseudoparticle entry, as deduced from
the reduction in GFP signal, was 92% at 10μM and 56% at 2μM.
Likewise, 1a produced 54% reduction at 2μM.
Activity against human coronavirus 229E. Given that te-
icoplanin and related glycopeptides were reported to have anti-coro-
navirus activity [10,11], we evaluated a subset of the newly synthe-
sized compounds against human coronavirus 229E, using two comple-
mentary methods, i.e. CPE reduction in human embryonic lung (HEL)
fibroblast cells and virus yield reduction in human lung carcinoma
A549 cells. Among Series 1, 2 and 3, we tested the analogues carrying
alkyl groups of intermediate length, i.e. n-butyl and n-hexyl; for Series
6, the entire series was tested. The antiviral activity values obtained
(see Table S6 in Supporting Information) in HEL and A549 cells
showed nice agreement. In A549 cells, several compounds produced
2-log10 (i.e. 100-fold) reduction in coronavirus yield at a concen-
tration of ∼10μM, with no or minimal cytotoxicity at 50μM. The
alkanesulfonamide derivatives 77 and 79 displayed potent anti-coro-
navirus activity in terms of EC50 (∼2μM) and SI (ratio of MCC to
EC50: 11 for 77 and 13 for 79). Within the same series, the p-tolue
Fig. 2. Structure of aniline-based influenza virus fusion inhibitors 80 and 81. (See ref.
[26]. compounds 9d and 14a, respectively).
Fig. 3. Inhibitory effect on cell entry of influenza virus HA- and NA-bearing
lentiviral pseudoparticles. The GFP-expressing particles carrying H1-HA and N1-NA
(from A/PR/8/34) were transduced into MDCK cells in the presence of compounds
(X-axis: concentrations in μM), and GFP expression was quantified after three days in-
cubation. The two test compounds, 1a and 63, were tested in parallel with four control
compounds, i.e. SA-19, a lipophilic derivative of aglycoristocetin [16]; chloroquine; and
two aniline-based influenza fusion inhibitors, 80 and 81 [26]. Data are the mean ± SEM
of four independent experiments.
nesulfonamide analogue 72 was also nicely active and selective (SI:
19).
3. Conclusion
In summary, we synthesized and evaluated several derivatives of
teicoplanin pseudoaglycon in a systematic manner to obtain struc-
ture-activity relationships concerning the anti-influenza virus activity
of the compounds. Many of the lipoglycopeptides exhibit remarkable
activity against both influenza A and B viruses and showing, occasion-
ally, favorable selectivity index.
Based on the biological data, it became evident that inhibition of
influenza virus replication is not primarily dependent on the type or
complexity of the chemical bond or functional group between the gly-
copeptide N-terminus and the newly introduced fragments. The struc-
ture of the side chains, but even more the overall lipophilicity of the
compounds are the most influential on biological properties.
Hence, the presence of a lipophilic side chain is definitely a re-
quirement for antiviral activity. The optimal length of alkyl sub-
stituents, which is somewhat dependent on the structure of the linker,
is usually equivalent to 6–10 methylene groups. If the side chain car-
ries two alkyl groups, reduced length might be enough, e. g. double
butyl substitution. The incorporation of longer alkyl groups (>14 car-
bon atoms, Series 4) might also lead to active compounds, however
most of these proved to be highly cytotoxic. The latter was even noted
for some compounds with the optimum side chain lengths (e.g. 8–10).
Reducing the cytotoxicity with preservation of antiviral activity was
achieved by incorporation of the tetraethylene glycol linker. In some
cases, this modification led to an improvement, while other derivatives
became less active, probably due to a loss of required lipophilicity.
Analyzing the influence of the aryl substitution is more difficult,
since this type of substituent is only present in two compound series
(Series 4 and 6) in a smaller number. Nevertheless, these analogues
seem to display a similar relationship between lipophilicity, anti-in-
fluenza virus activity and cytotoxicity, as the alkyl substituted com-
pounds. Compounds containing one aromatic ring are usually not very
active nor cytotoxic. Two aromatic rings seem to boost antiviral ac-
tivity because of increased lipophilicity, but cytotoxicity also becomes
prominent. Interestingly, the two compounds that carried numerous
aromatic rings in the form of a highly bulky, lipo/hydrophilic side
chain were effective against one or more influenza virus strains with-
out causing serious cytotoxicity.
As mentioned earlier, it is likely that cytotoxicity of the lipogly-
copeptides increases with the compounds' ability to solubilize cellu-
lar membranes and with net lipophilicity. With bulky and amphiphilic
side chains, this effect might be weaker compared to more simple
structures such as alkyl chains which could easily insert into lipid
membranes. This could explain the apparent contradiction that some
analogues displayed very high lipophilicity without severe cytotoxic-
ity.
It is evident that the major challenge lies in designing the opti-
mal lipoglycopeptide structures to provide sufficient lipophilicity for
anti-influenza virus activity without causing serious cytotoxicity. As
we have demonstrated, high activity goes hand in hand with high tox-
icity in many instances. Still, our study proved that once an active
lead compound has been identified, it is possible to diminish its cy-
totoxicity by applying appropriate structural adjustments. Besides the
modifications described here, there are unlimited variations that could
lead to derivatives with excellent biological profiles. Moreover, as we
have seen, the promising antiviral activity is not limited to influenza
virus since some of our derivatives also displayed activity against hu
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man coronavirus. This makes this class of lipoglycopeptides a relevant
class for further investigation [27].
4. Experimental section
4.1. General information
Propargylamine and alkyl thiols were purchased from Sigma
Aldrich Chemical Co., dansyl chloride, benzenesulfonyl chloride,
p-acetamidobenzenesulfonyl chloride, biphenylsulfonyl chloride were
purchased from Tokyo Chemical Industry Co., Ltd., alkyl sulfonyl
chlorides were prepared from the corresponding thiols using a litera-
ture method [28], triethylene glycol 2-aminoethyl propargyl ether,
[29] 1-mercapto-11-hydroxy-3,6,9-trioxaundecane, [30]
1-azido-11-hydroxy-3,6,9-trioxaundecane, [31] 2,3-dibromoma-
leimide 3 [32], teicoplanin pseudoaglycon 11 [9] and azido teicoplanin
pseudoaglycon 25 [9] were also prepared according to literature pro-
cedures. TLC analysis was performed on Kieselgel 60 F254 (Merck)
silica gel plates with visualization by immersing in ammonium-molib-
date solution followed by heating or Pauly-reagent in the case of te-
icoplanin-derivatives. Flash column chromatography was performed
on silica gel 60 (Merck 0.04–0.063mm). Organic solutions were dried
over Na2SO4 and concentrated under vacuum. The
1H (360, 400 and
500MHz) and 13C NMR (90.54, 100.28, 125.76MHz) spectra were
recorded with Bruker DRX-360, Bruker DRX-400 and Bruker Avance
II 500 spectrometers. Chemical shifts are referenced to Me4Si or
DSS (0.00 ppm for 1H) and to solvent signals (CDCl3: 77.16ppm,
DMSO‑d6: 39.52ppm for
13C). MS (MALDI-TOF) analysis was car-
ried out in positive reflectron mode on a BIFLEX III mass spec-
trometer (Bruker, Germany) with delayed-ion extraction. The ma-
trix solution was a saturated solution of 2,4,6-trihydroxyacetophenone
(2,4,6-THAP) in DMF. Elemental analysis (C, H, N, S) was performed
on an Elementar Vario MicroCube instrument.
General method A for the preparation of N-ethoxycarbonyl
bis-alkylthio maleimides (5b, 6b, 9b, 32b).
To a stirred solution of bis-alkylthio maleimide (1.0 equiv.) in
dry acetone (20mL) K2CO3 (1.2 equiv.) and ethyl chloroformate (1.2
equiv.) were added under an argon atmosphere and stirred for 3hat
room temperature. The reaction mixture was diluted with CH2Cl2, fil-
tered through a pad of Celite and concentrated. The crude product was
used for further steps without purification.
General method B for preparing N-propargyl-bis-alkylthio
maleimides or N-TEG-propargyl-bis-alkylthio maleimides.
To a stirred solution of N-ethoxycarbonyl bis-alkylthio maleimide
[24] (1.0 equiv.) in CH2Cl2 (30 mL) propargylamine or triethylene
glycol 2-aminoethyl propargyl ether (1.25 equiv.) and Et3N (1.25
equiv.) were added under an argon atmosphere and stirred overnight
at room temperature. The reaction mixture was diluted with CH2Cl2,
washed with cc. NH4Cl and water twice, dried over Na2SO4, filtered
and concentrated. The crude product was purified by flash chromatog-
raphy to give the desired compound.
4.2. General method C for azide-alkyne click reaction
To a stirred solution of azide (1.0 equiv.) in dry DMF (5 mL)
the alkyne compound (1.0–1.5 equiv.), Et3 (1.0 equiv.) and Cu(I)I
(20–30 mol%) were added under an argon atmosphere and stirred for
overnight at room temperature. The reaction mixture was concen-
trated, and the crude product was purified by flash chromatography. In
the case of teicoplanin derivatives toluene/methanol (+1.0 v/v% acetic
acid) or acetonitrile/water mixtures were used as eluent.
4.3. General method D for alkylation
To a stirred suspension of NaH (2.0 equiv.) in dry DMF (5mL) the
alcohol (1 equiv.) was added dropwise at 0 °C. After 30min alkyl-bro-
mide (1.5 equiv.) was added dropwise and stirred for 3 h. The reac-
tion mixture was quenched with methanol, concentrated, diluted with
DCM, washed twice with water, dried over Na2SO4, filtered and con-
centrated. The crude product was purified by flash chromatography to
give the desired compound.
4.4. General method E for the preparation of sulfonamides
To a stirred solution of teicoplanin pseudoaglycon (1.0 equiv.) in
dry pyridine (3–5mL) the corresponding sulfonyl chloride (1.3–1.4
equiv.) was added at once and the reaction mixture was allowed to
stir at room temperature for 4h. Afterwards, methanol was added to
quench the reaction, the solvent was evaporated, and the crude product
was purified by flash chromatography using gradient elution starting
from 100% acetonitrile to 90% acetonitrile 10% water.
Compounds 5a and 5b. To a stirred solution of 2,3-dibromoma-
leimide 3 [32] (255mg, 1.0mmol) in CH2Cl2 (20 mL) Et3N (279μL,
2.0mmol) and n-butyl-mercaptan (226μl, 2.1mmol) were added un-
der an argon atmosphere and stirred for 3hat room temperature. The
reaction mixture was evaporated, and the crude product was puri-
fied by flash chromatography (hexanes:acetone = 9:1) to give the de-
sired compound 5a (243 mg, 89%) as a yellow powder. 1H NMR
(400 MHz, CDCl3): δ 8.07 (s, 1H, NH), 3.29 (t, J = 7.3Hz, 4H, 2 x
S-CH2), 1.69–1.58 (m, 4H), 1.52–1.35 (m, 4H), 0.93 (t, J = 7.3Hz,
6H, 2 x CH3).
13C NMR (101MHz, CDCl3): δ 166.7 (2C, 2x C=O);
136.8 (C=C); 32.6, 31.6, 21.7 (6C, 6x CH2); 13.7 (2C, 2x CH3). MS
(ESI): m/z calculated for C12H19NO2S2 + Na
+ [M + Na+]: 296.075.
Found: 296.073. Compound 5a was converted into the N-ethoxycar-
bonyl compound according to general method A. The crude com-
pound 5b was used in further steps without purification.
Compounds 6a and 6b. To a stirred solution of 2,3-dibromo-
maleimide (510mg, 2.0mmol) in CH2Cl2 (20 mL) Et3N (558μL,
4.0mmol) and n-hexyl-mercaptan (600μl, 4.2mmol) were added un-
der an argon atmosphere and stirred for 3hat room temperature. The
reaction mixture was evaporated, and the crude product was purified
by flash chromatography (hexanes:ethyl acetate = 9:1) to give com-
pound 6a (526mg, 80%) as a yellow powder. 1H NMR (400MHz,
CDCl3): δ 7.88 (s, 1H), 3.28 (t, J = 7.4Hz, 4H, 2 x -SCH2), 1.70–1.59
(m, 4H, CH2), 1.47–1.37 (m, 4H), 1.35–1.24 (m, 8H), 0.89 (t,
J = 6.7Hz, 6H, 2x CH3).
13C NMR (101MHz, CDCl3): δ 166.6 (2C);
136.8 (C=C); 31.9, 31.4, 30.6, 28.3 (8C, 8x CH2); 22.6 (2C, 2 x
CH2S); 14.1 (2C, 2x CH3). MS (ESI): m/z calculated for
C16H27NO2S2 + Na
+ [M + Na+]: 352.138. Found: 352.201. Compound
6a was converted into N-ethoxycarbonyl compound according to gen-
eral method A. The crude compound 6b was used in further steps
without purification.
Compounds 9a and 9b. To a stirred solution of 2,3-dibromo-
maleimide (510 mg, 2.0mmol) in CH2Cl2 (20mL) Et3N (277μl,
2.0mmol) was added, then cooled to 0°C and n-propyl-mercaptan
(186μl, 2.0mmol) dissolved in CH2Cl2 (10 mL) was added dropwise
under an argon atmosphere and stirred for 5h. The reaction mixture
was concentrated, and the crude product was purified by flash chro-
matography (hexanes:ethyl acetate = 9:1) to give the desired interme-
diate (261 mg, 52%) as a yellow powder. To a stirred solution of the
intermediate (261mg, 1.04mmol) in CH2Cl2 (20 mL) Et3N (160μl,
1.1mmol) and n-dodecyl-mercaptan (264μl, 1.1mmol) were added
under an argon atmosphere and stirred for 30min. The reaction mix
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ture was concentrated, and the crude product was purified by flash
chromatography (hexanes:ethyl acetate = 95:5) to give the compound
9a (273 mg, 71%) as a yellow powder. 1H NMR (400 MHz, CDCl3):
δ 7.60 (s, 1H, NH), 3.34–3.22 (m, 4H, 2x S-CH2), 1.74–1.59 (m, 4H),
1.45–1.37 (m, 2H), 1.30–1.21 (m, 16H), 1.03 (t, J = 7.4Hz, 3H), 0.88
(t, J = 6.8Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 166.61, 166.40,
(2C, 2 x C=O) 136.98, 136.71, (2C, 2 x C-S) 33.79, 32.04, 31.95,
30.59, 29.76, 29.69, 29.60, 29.48, 29.24, 28.62, 24.03, 22.82, (13C,
13 x CH2) 14.26, 13.23. (2C, 2 x CH3). MS (MALDI-TOF): m/z cal-
culated for C19H33NO2S2 + Na
+ [M + Na+]: 394.18. Found: 394.25.
Compound 9a was converted into N-ethoxycarbonyl compound ac-
cording to general method A. The crude compound 9b was used in
further steps without purification.
Compound 13. To a stirred solution of teicoplanin pseudoagly-
con [9] (224 mg, 0.16mmol) in dry DMF (5 mL) N-ethoxycarbonyl
bis-alkylthio maleimide 5b (43 mg, 0.16mmol) and Et3N (22μl,
0.16mmol) were added under an argon atmosphere and stirred for
overnight at room temperature. The reaction mixture was concen-
trated, and the crude product was purified by flash chromatogra-
phy (toluene:methanol = 1:1) to give 13 (68 mg, 26%), as a yellow
powder. NMR data can be found in Table S1(supporting informa-
tion). MS (MALDI-TOF): m/z calculated for C78H74Cl2N8O25S2 + Na
+
[M + Na+]: 1679.35. Found: 1679.5.
Compound 14. Compound 6b (53 mg, 0.16mmol) was coupled
to teicoplanin pseudoaglycon (224 mg, 0.16mmol) according to the
procedure described for compound 13. The crude product was pu-
rified by flash chromatography (toluene:methanol = 1:1) to give 14
(61 mg, 22%), as a yellow powder. NMR data can be found in Table
S1(supporting information). MS (MALDI-TOF): m/z calculated for
C82H82Cl2N8O25S2 + Na
+ [M + Na+]: 1735.41. Found: 1734.99.
Compound 17. Compound 9b (27 mg, 71μmol) was coupled to
teicoplanin pseudoaglycon (100 mg, 71μmol) according to the pro-
cedure described for compound 13. The crude product was purified
by flash chromatography (toluene:methanol = 1:1) to give 17 (23mg,
18%), as a yellow powder. NMR data can be found in Table S1
(supporting information). MS (MALDI-TOF): m/z calculated for
C85H88Cl2N8O25S2 + Na
+ [M + Na+]: 1777.46. Found: 1777.47.
Compound 19. The title compound was prepared by the reac-
tion of 4b (63 mg, 0.2mmol) and propargylamine according to general
method B. The crude product was purified by flash chromatography in
hexanes:acetone = 9:1, to give 19 (48mg, 85%) as a yellow syrup. 1H
NMR (360 MHz, CDCl3): δ 4.27 (d, J = 2.5Hz, 2H, NCH2), 3.38–3.16
(m, 4H, 2 x SCH2), 2.23 (t, J = 2.5Hz, CH2CCH), 1.80–1.60 (m, 4H, 2
x CH2), 1.03 (t, J = 7.3Hz, 6H, 2 x CH3);
13C NMR (91MHz, CDCl3):
δ 165.3 (2C, 2 x C=O), 136.1 (2C, 2 x C=C), 71.6 (1C, CH), 33.8 (2C,
2 x SCH2) 27.6 (NCH2), 24.0 (1C, CH2), 13.2 (2C, 2x CH3). Elemen-
tal analysis calculated (%) for C13H17NO2S2: C 55.10, H 6.25, N 4.94,
S 22.62. Found: C 54.96, H 6.42, N 4.79, S 22.45.
Compound 20. Compound 20 was prepared by the reaction of 5b
(117 mg, 0.34mmol) and propargylamine according to general method
B. The crude product was purified by flash chromatography in hexa-
nes:ethyl acetate = 9:1, to give the title compound (89 mg, 84%) as a
yellow powder. 1H NMR (400 MHz, CDCl3): δ 4.27 (d, J = 3.3Hz,
2H), 3.31 (t, J = 7.4Hz, 4H), 2.23 (t, J = 2.5Hz, 1H), 1.69–1.59 (m,
4H), 1.50–1.40 (m, 4H), 0.93 (t, J = 7.4Hz, 6H, CH3).
13C NMR
(101 MHz, CDCl3): δ 165.4 (2C, 2x C=O); 136.1 (C=C); 71.6 (1C,
C≡CH) 32.6, 31.7 (4C, 4x CH2); 27.6 (1C, N-CH2); 21.8 (2C, 2 x
CH2S); 13.7 (2C, 2x CH3). MS (MALDI-TOF): m/z calculated for
C15H21NO2S2 + Na
+ [M + Na+]: 334.09. Found: 334.12.
Compound 21. Compound 6b (230 mg, 0.57mmol) and propar-
gylamine were reacted according to general method B. The crude
product was purified by flash chromatography in hexanes:ethyl-ac-
etate = 9:1, to give 21 (155 mg, 74%) as a yellow powder. 1H NMR
(400 MHz, CDCl3): δ 4.27 (d, J = 2.3Hz, 2H), 3.30 (t, J = 7.4Hz, 4H),
2.22 (t, J = 2.3Hz, 1H), 1.65 (m, 4H), 1.42 (m, 4H), 1.35–1.24 (m,
8H), 0.89 (t, J = 6.8Hz, 6H). 13C (101 MHz, CDCl3): δ 165.4 (2C 2x
C=O); 136.1 (C=C); 71.6 (1C, C≡CH) 32.0, 31.4, 30.5, 28.3, (8C, 8x
CH2); 27.6 (1C, N-CH2); 22.6 (2C, 2 x CH2S); 14.1 (2C, 2x CH3). MS
(MALDI-TOF): m/z calculated for C19H29NO2S2 + Na
+ [M + Na+]:
390.15. Found: 390.3.
Compound 22. The desired compound was prepared by the re-
action of 7b (341 mg, 0.74mmol) and propargylamine according to
general method B. The crude product was purified by silica gel chro-
matography in n-hexanes:ethyl acetate = 9:1, to give 22 (172 mg, 55%)
as a yellow syrup. 1H NMR (400 MHz, CDCl3): δ 4.27 (4H, d,
J = 2.4Hz, 2 x CH2), 3.34–3.26 (4H, m, 2 x SCH2), 2.22 (1H, t,
J = 2.5Hz, CH), 1.69–1.60 (4H, m, 2 x CH2), 1.45–1.36 (4H, m,
2 x CH2), 1.27 (16H, br s, 8 x CH2), 0.88 (6H, t, J = 6.8Hz, 2 x
CH3);
13C NMR (101MHz, CDCl3): δ 165.4 (2 x C=O), 136.1 (C=C),
71.6 (CH), 32.0 (N-CH2), 31.9, 30.6, 29.2, 29.2, 28.6, 27.5 (CH2),
22.7 (S-CH2), 14.2 (CH3). MS (MALDI-TOF): m/z calculated for
C23H37NO2S2 + Na
+ [M + Na+]: 446.22. Found: 446.19.
Compound 23. The reaction between compound 8b (114mg,
0.2mmol) and propargylamine was carried out according to general
method B, followed by flash chromatography (hexanes:acetone = 8:2),
which gave compound 23 (83 mg, 78%) as a yellow syrup. 1H NMR
(360 MHz, CDCl3): δ 4.27 (d, J = 2.5Hz, 2H), 3.36–3.22 (m, 4H), 2.21
(t, J = 2.5Hz, 1H), 1.64 (dq, J = 13.6, 6.5, 5.9Hz, 4H), 1.48–1.36 (m,
4H), 1.26 (s, 32H), 0.88 (t, J = 6.7Hz, 6H). Elemental analysis calcu-
lated (%) for C31H53NO2S2: C 69.48, H 9.97, N 2.61, S 11.97. Found:
C 69.32, H 10.18, N 2.55, S 11.86.
Compound 24. Compound 10b (107mg, 0.15mmol) was reacted
with propargylamine and worked up according to general method B.
The crude product was used in the next step without further purifica-
tion (see compound 31 below).
Compound 26. Compound 19 (25 mg, 0.09mmol) and azido te-
icoplanin pseudoaglycon 25 (107 mg, 0.075mmol) were reacted ac-
cording to general method C to give 26 (54mg, 42%) as a yellow pow-
der. NMR data can be found in Table S2 (supporting information).
MS (MALDI-TOF): m/z calculated for C79H73Cl2N11O25S2 + Na
+
[M + Na+]: 1732.35. Found: 1732.62.
Compound 27. The reaction of compound 20 (31 mg, 0.10mmol)
and azido teicoplanin pseudoaglycon 25 (107 mg, 0.075mmol) ac-
cording to general method C gave compound 27 (54 mg, 41%) as a
yellow powder after purification. NMR data can be found in Table
S2 (supporting information). MS (MALDI-TOF): m/z calculated for
C81H77Cl2N11O25S2 + Na
+ [M + Na+]: 1760.38. Found: 1760.60.
Compound 28. The glycopeptide 28 was prepared by the reac-
tion of compound 21 (37mg, 0.10mmol) and azido teicoplanin
pseudoaglycon 25 (107 mg, 0.075mmol) according to general method
C. After purification the title compound was obtained as a yellow
powder (56 mg, 42%). NMR data can be found in Table S2 (sup-
porting information). MS (MALDI-TOF): m/z calculated for
C85H85Cl2N11O25S2 + Na
+ [M + Na+]: 1816.44. Found: 1815.99.
Compound 29. Compound 22 (43 mg, 0.1mmol) and azido te-
icoplanin pseudoaglycon 25 (107 mg, 0.075mmol) were reacted ac-
cording to general method C to give 29 (57mg, 41%) as a yellow pow-
der. NMR data can be found in Table S2 (supporting information).
MS (MALDI-TOF): m/z calculated for C89H93Cl2N11O25S2 + Na
+
[M + Na+]: 1872.51. Found: 1872.63.
Compound 30. The reaction of compound 23 (48 mg, 0.09mmol)
and azido teicoplanin pseudoaglycon 25 (107 mg, 0.075mmol) ac-
cording to general method C gave 30 (58 mg, 39%) as a yellow pow
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der. NMR data can be found in Table S2. MS (MALDI-TOF): m/z
calculated for C97H109Cl2N11O25S2 + Na
+ [M + Na+]: 1984.63. Found:
1984.93.
Compound 31. Compound 24 (70 mg, ∼0.09mmol) was reacted
with azido teicoplanin pseudoaglycon 25 (107 mg, 0.075mmol) ac-
cording to general method C to give 31 (61mg, 39%) as a yellow pow-
der. NMR data can be found in Table S2 (supporting information).
MS (MALDI-TOF): m/z calculated for C97H97Cl2N11O35S2 + Na
+
[M + Na+]: 2132.49. Found: 2132.62.
Compounds 32a and b. To a stirred solution of 2,3-dibromo-
maleimide (255 mg, 1.0mmol) in CH2Cl2 (20 mL) Et3N (2.0 mmol,
278μL) and 1-Mercapto-11-hydroxy-3,6,9-trioxaundecane (402μl,
2.1mmol) were added under an argon atmosphere and stirred for 3hat
room temperature. The reaction mixture was evaporated, and the crude
product was converted into N-ethoxycarbonyl compound and worked
up according to general method A yielding compound 32b which was
used in further steps without purification.
Compound 33. The reaction of 4b (150 mg, 0.47mmol) and tri-
ethylene glycol 2-aminoethyl propargyl ether was carried out ac-
cording to general method B. After flash chromatography in hexa-
nes:acetone = 9:1 the desired compound 33 was obtained (186mg,
86%) as a yellow syrup. 1H NMR (400 MHz, CDCl3): δ 4.26–4.14 (m,
2H, CH2), 3.76–3.56 (m, 16H, 8 x CH2), 3.26 (t, J = 7.3Hz, 4H, 2 x
SCH2), 2.48–2.41 (m, 1H, CH), 1.75–1.61 (m, 4H, 2 x CH2), 1.03 (t,
J = 7.3Hz, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3): δ 166.6 (2C,
2 x C=O), 135.9 (2C, 2 x C=C), 74.6 (CH≡C), 70.7, 70.7, 70.5, 70.1,
69.2, 67.9, 58.5 (8C, 8 x OCH2), 37.8 (NCH2), 33.8 (2C, 2 x SCH2),
24.0 (2C, 2 x CH2), 13.2 (2C, 2 x CH3). Elemental analysis calculated
(%) for C21H33NO6S2: C 54.88, H 7.24, N 3.05, S 13.95. Found: C
54.80, H 7.35, N 2.99, S 13.78.
Compound 34. Compound 5b (117 mg, 0.34mmol) was reacted
with triethylene glycol 2-aminoethyl propargyl ether according to
general method B. The crude product was purified by flash chro-
matography in hexanes:ethyl acetate = 7:3, to give 34 (154 mg, 93%)
as a yellow syrup. 1H: (400MHz, CDCl3): δ 4.21 (d, J = 2.4Hz, 2H),
3.73–3.58 (m, 16H), 3.28 (t, J = 7.4Hz, 4H), 2.44 (t, J = 2.4Hz, 1H),
1.69–1.58 (m, 4H), 1.51–1.39 (m, 4H), 0.93 (t, J = 7.3Hz, 6H). 13C
NMR (101 MHz, CDCl3): δ 166.6 (2C, 2x C=O); 135.8 (2C, 2 x C=C);
74.6 (CH≡C), 70.7, 70.6, 70.5, 70.1, 69.2, 67.9, 58.5 (8C, 8 x OCH2),
37.8 (NCH2), 32.6, 31.6 (4C, 4x CH2); 21.7 (2C, 2 x CH2S); 13.7 (2C,
2x CH3) MS (ESI): m/z calculated for C23H37NO6S2 + Na
+ [M + Na+]:
510.20. Found: 510.21.
Compound 35. Compound 35 was prepared by the reaction of 6b
(230 mg, 0.57mmol) and triethylene glycol 2-aminoethyl propargyl
ether according to general method B. The crude product was purified
by flash chromatography in hexanes:ethyl acetate = 85:15, yielding the
title compound (236mg, 76%) as a yellow syrup. 1H NMR (400MHz,
CDCl3): δ 4.20 (d, J = 2.4Hz, 2H), 3.73–3.59 (m, 16H), 3.31–3.24 (m,
4H), 2.44 (t, J = 2.3Hz, 1H), 1.64 (dt, J = 15.1, 7.4Hz, 4H), 1.42 (dt,
J = 14.3, 7.2Hz, 4H), 1.36–1.23 (m, 8H), 0.89 (t, J = 6.9Hz, 6H). 13C
NMR (101MHz, CDCl3): δ 166.6 (2C, C=O), 135.7 (2C, 2 x C=C),
74.6 (CH≡C), 70.6, 70.6, 70.4, 70.0, 69.1, 67.9, 58.4 (8C, 8 x OCH2),
37.8 (NCH2), 31.9, 31.3, 30.4, 28.2, 22.5 (10C, 10 x CH2), 14.0 (2C,
2 x CH3). MS (MALDI-TOF): m/z calculated for C27H45NO6S2 + Na
+
[M + Na+]: 566.26. Found: 566.25.
Compound 36. Compound 7b (150 mg, 0.33mmol) and triethyl-
ene glycol 2-aminoethyl propargyl ether were reacted according
to general method B. The crude product was purified by flash chro-
matography in hexanes:acetone = 8:2, to give 36 (112 mg, 57%) as
a yellow syrup. 1H NMR (400MHz, CDCl3): δ 4.21 (d, J = 2.4Hz,
2H), 3.72–3.59 (m, 16H), 3.32–3.23 (m, 4H), 2.43 (t, J = 2.4 Hz, 1H),
1.64 (dt, J = 15.0, 7.4Hz, 4H), 1.46–1.36 (m, 4H), 1.30 (dt, J = 8.7,
5.1Hz, 16H), 0.88 (t, J = 6.8Hz, 6H). 13C NMR (101 MHz, CDCl3): δ
166.7 (2C, 2 x C=O), 135.9 (2C, 2 x C=C), 74.6 (CH≡C), 70.8, 70.7,
70.5, 70.1, 69.3, 68.0, 58.5 (8C, 8 x OCH2), 37.8 (NCH2), 32.0, 31.9
(2C, 2 x SCH2), 30.6, 29.3, 29.3, 28.7, 22.8 (10C, 10 x CH2), 14.2
(2C, 2 x CH3). Elemental analysis calculated (%) for C31H53NO6S2:
C 62.07, H 8.91, N 2.33, S 10.69. Found: C 61.85, H 9.07, N 2.25, S
10.60.
Compound 37. Compound 8b (150 mg, 0.26mmol) and triethyl-
ene glycol 2-aminoethyl propargyl ether were reacted according
to general method B. The crude product was purified by silica gel
chromatography in hexanes:acetone = 8:2, to give 37 (135 mg, 72%)
as a yellow syrup. 1H NMR (400 MHz, CDCl3): δ 4.21 (d, J = 2.4Hz,
2H), 3.73–3.57 (m, 16H), 3.27 (t, J = 7.4Hz, 4H), 2.43 (t, J = 2.4Hz,
1H), 1.69–1.59 (m, 4H), 1.40 (dd, J = 13.2, 7.5Hz, 4H), 1.34–1.20
(m, 32H), 0.88 (t, J = 6.8Hz, 6H). 13C NMR (101 MHz, CDCl3): δ
166.7 (2C, 2 x C=O), 135.8 (2C, 2 x C=C), 74.6 (CH≡C), 70.7, 70.7,
70.5, 70.1, 69.2, 67.9, 58.5 (8C, 8 x OCH2), 37.6 (NCH2), 32.0 (2C,
2 x SCH2), 30.6, 29.8, 29.7, 29.6, 29.5, 29.2, 28.7, 22.8 (20C, 20
x CH2), 14.2 (2C, 2 x CH3). MS (MALDI-TOF): m/z calculated for
C39H69NO6S2 + Na
+ [M + Na+]: 734.45. Found: 735.01.
Compound 38. The reaction of 10b (381 mg, 0.53mmol) and tri-
ethylene glycol 2-aminoethyl propargyl ether according to gen-
eral method B gave a crude product that was purified by flash chro-
matography in hexanes:acetone = 7:3, yielding 38 (340mg, 75%) as
a yellow syrup. 1H NMR (400MHz, CDCl3): δ 5.51 (d, J = 4.9Hz,
2H, H-1), 4.62 (dd, J = 7.9, 2.1Hz, 2H), 4.35–4.27 (m, 4H), 4.21 (d,
J = 2.0Hz, 2H), 3.98 (t, J = 6.8Hz, 2H), 3.73–3.57 (m, 16H), 3.57–3.34
(m, 4H), 2.45 (t, J = 2.4Hz, 1H, CH), 1.46 (d, J = 14.6Hz, 12H), 1.32
(d, J = 3.9Hz, 12H). 13C NMR (101 MHz, CDCl3): δ 166.3 (2C, 2 x
C=O), 135.9 (2C, 2 x C=C), 109.5, 108.8 (4C, 4 x Cq), 96.6 (2C, 2 x
CH), 74.5 (1C, CH), 71.6, 71.0 (4C, 4 x CH), 70.7, 70.6 (3C, 3 x CH2)
70.5 (2C, 2 x CH), 70.5 (1C, CH2), 70.1, 69.2 (2C, 2 x CH2), 68.0
(2C, 2 x CH), 67.8 (1C, CH2), 58.5 (1C, CH2) 37.8 (1C, NCH2), 31.8
(2C, 2 x C-6,6’), 26.0 (4C, 4 x CH3), 25.0, 24.5 (4C, 4 x CH3). MS
(MALDI-TOF): m/z calculated for C39H57NO16S2 + Na
+ [M + Na+]:
882.30. Found: 882.30.
Compound 39. To a stirred solution of 32b (62 mg, 0.11mmol)
triethylene glycol 2-aminoethyl propargyl ether was added and the
reaction was carried out according to general method B. The reac-
tion was worked up and used in its crude form for the synthesis of the
final product 46.
Compound 40 The reaction between compound 33 (46mg,
0.1mmol) and azido teicoplanin pseudoaglycon 25 (107mg,
0.075mmol) was carried out according to general method C to give 40
(59 mg, 42%) as a yellow powder. NMR data can be found in Table
S3. MS (MALDI-TOF): m/z calculated for C87H89Cl2N11O29S2 + Na
+
[M + Na+]: 1908.45. Found: 1908.60.
Compound 41. The reaction between compound 34 (49mg,
0.1mmol) and azido teicoplanin pseudoaglycon 25 (107mg,
0.075mmol) was carried out according to general method C to give 41
(34 mg, 24%) as a yellow powder. NMR data can be found in Table
S3. MS (MALDI-TOF): m/z calculated for C89H93Cl2N11O29S2 + Na
+
[M + Na+]: 1936.49. Found: 1936.70.
Compound 42. The reaction between compound 35 (54mg,
0.1mmol) and azido teicoplanin pseudoaglycon 25 (107mg,
0.075mmol) was carried out according to general method C to give 42
(27 mg, 18%) as a yellow powder. NMR data can be found in Table
S3. MS (MALDI-TOF): m/z calculated for C93H101Cl2N11O29S2 + Na
+
[M + Na+]: 1992.55. Found: 1991.9.
Compound 43. Glycopeptide derivative 43 was obtained by car-
rying out the reaction between compound 36 (60mg, 0.1mmol) and
azido teicoplanin pseudoaglycon 25 (107mg, 0.075mmol) according
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to general method C, giving 43 (65 mg, 43%) as a yellow powder.
NMR data can be found in Table S3. MS (MALDI-TOF): m/z cal-
culated for C97H109Cl2N11O29S2 + Na
+ [M + Na+]: 2048.61. Found:
2048.68.
Compound 44. Compound 37 (71 mg, 0.1mmol) and azido te-
icoplanin pseudoaglycon 25 (107 mg, 0.075mmol) were reacted ac-
cording to general method C to give 44 (44mg, 27%) as a yellow pow-
der. NMR data can be found in Table S3. MS (MALDI-TOF): m/z cal-
culated for C105H125Cl2N11O29S2 + Na
+ [M + Na+]: 2160.74. Found:
2160.89.
Compound 45. To a stirred solution of azido teicoplanin
pseudoaglycon 25 (107 mg, 0.075mmol)in DMF, compound 38
(86 mg, 0.1mmol) was added and the reaction was carried out accord-
ing to general method C to give 45 (57 mg, 33%) as a yellow pow-
der. NMR data can be found in Table S3. MS (MALDI-TOF): m/z cal-
culated for C105H113Cl2N11O39S2 + Na
+ [M + Na+]: 2308.59. Found:
2308.62.
Compound 46. Compound 39 (42 mg, 57μmol) and azido te-
icoplanin pseudoaglycon 25 (82mg, 57μmol) were reacted accord-
ing to general method C to give 46 (27 mg, 22%) as a yellow pow-
der. NMR data can be found in Table S3. MS (MALDI-TOF): m/z
calculated for C97H109Cl2N11O37S2 + Na
+ [M + Na+]: 2176.57. Found:
2176.86.
Compound 52. 1-Azido-11-hydroxy-3,6,9-trioxaundecane 47
(413 mg, 1.89mmol) was coupled with propargyl ether 48 (265mg,
2.36mmol) according to general method C. The crude product was
purified by flash chromatography (hexanes:acetone = 6:4) resulting in
52 (405 mg, 52%) as a yellowish syrup. 1H NMR (360 MHz, CDCl3):
δ 7.78 (s, 1H, C=CH), 4.62 (s, 2H, OCH2C), 4.58–4.51 (m, 2H),
3.88 (t, J = 5.1Hz, 2H), 3.76–3.70 (m, 2H) 3.67 (dd, J = 6.0, 2.7Hz,
2H), 3.61 (q, J = 4.5Hz, 8H), 3.53 (t, J = 6.6Hz, 2H), 2.94 (s, 1H,
OH), 1.58 (dt, J = 14.5, 6.7Hz, 2H), 1.37 (dq, J = 14.5, 7.3Hz, 2H),
0.91 (t, J = 7.3Hz, 3H). 13C NMR (91 MHz, CDCl3): δ 145.3 (1C,
C=CH), 123.7 (1C, C=CH), 72.6, 70.6, 70.5, 70.4, 70.3, 69.5, 64.3
(8C, 8 x OCH2), 61.6 (1C, CH2OH), 50.2 (1C, NCH2), 31.7 (1C,
CH2), 19.3 (1C, CH2), 13.9 (1C, CH3). MS (ESI): m/z calculated for
C15H29N3O5 + Na
+ [M + Na+]: 354.200. Found: 354.201.
Compound 53. Compound 47 (444 mg, 2.03mmol) and propar-
gyl ether 49 (284 mg, 2.03mmol) were reacted according to general
method C. The crude product was purified by flash chromatography
(hexanes:acetone = 6:4) resulting in 53 (542 mg, 74%) as a yellowish
syrup. 1H NMR (360 MHz, CDCl3): δ 7.79 (s, 1H, C=CH), 4.62 (s, 2H,
OCH2), 4.55 (t, J = 5.0Hz, 2H), 3.92–3.84 (m, 2H, OCH2), 3.76–3.69
(m, 2H), 3.69–3.57 (m, 10H), 3.52 (t, J = 6.7Hz, 2H), 3.09 (s, 1H,
OH), 1.66–1.53 (m, 2H), 1.41–1.24 (m, 6H) 0.88 (t, J = 6.6Hz, 3H,
CH3).
13C NMR (101 MHz, CDCl3): δ 145.2 (1C, C=CH), 123.8 (1C,
C=CH), 72.6, 70.8, 70.5, 70.4, 70.2, 69.3, 64.2 (8C, 8 x OCH2), 61.5
(1C, CH2OH), 50.2 (1C, NCH2), 31.6, 29.6, 25.7, 22.6 (4C, 4 x CH2),
14.0 (1C, CH3). MS (ESI): m/z calculated for C17H33N3O5 + Na
+
[M + Na+]: 382.231. Found: 382.226.
Compound 54. Compound 47 (400 mg, 1.83mmol) and propargyl
ether 50 (462 mg, 2.75mmol) according to general method C. After
purification by flash chromatography (hexanes:acetone = 7:3) 54 was
obtained (480 mg, 68%) as a yellowish syrup. 1H NMR (360MHz,
CDCl3): δ 7.77 (s, 1H, C=CH), 4.62 (s, 2H, OCH2), 4.55 (t, J = 5.0Hz,
2H), 3.95–3.82 (m, 2H, OCH2), 3.75–3.70 (m, 2H), 3.69–3.56 (m,
10H), 3.51 (t, J = 6.7Hz, 2H), 2.94 (s, 1H, OH), 1.66–1.51 (m, 2H),
1.39–1.18 (m, 10H), 0.87 (t, J = 6.7Hz, 3H, CH3).
13C NMR (91MHz,
CDCl3): δ 145.3 (1C, C=CH), 123.7 (1C, C=CH), 72.6, 70.8, 70.6,
70.5, 70.3, 69.6, 64.3 (8C, 8 x OCH2), 61.7 (1C, CH2OH), 50.2
(1C, NCH2), 31.8, 29.7, 29.5, 29.3, 26.1, 22.7
(6C, 6 x CH2), 14.1 (1C, CH3). MS (ESI): m/z calculated for
C19H37N3O5 + Na
+ [M + Na+]: 410.263. Found: 410.258.
Compound 55. Compound 47 (260 mg, 1.19mmol) was coupled
with propargyl ether 51 (235mg, 1.30mmol) according to general
method C. The crude product was purified by flash chromatogra-
phy (hexanes:acetone = 7:3) resulting in 55 (463 mg, 86%) as a slight
yellow syrup. 1H NMR (360MHz, CDCl3): δ 7.79 (s, 1H, C=CH),
4.62 (s, 2H, OCH2), 4.55 (t, J = 5.0Hz, 2H), 3.88 (t, J = 5.0Hz, 2H),
3.75–3.70 (m, 2H, OCH2), 3.68–3.64 (m, 2H), 3.65–3.57 (m, 8H),
3.52 (t, J = 6.7Hz, 2H), 1.58 (dq, J = 10.1, 5.0, 3.4Hz, 2H), 1.26 (br
s, 14H, 7 x CH2), 0.88 (t, J = 6.8Hz, 3H, CH3).
13C NMR (91MHz,
CDCl3): δ 72.6, 70.9, 70.5, 70.4, 70.3, 69.6, 64.3 (8C, 8 x OCH2), 61.7
(1C, CH2OH), 50.3 (1C, NCH2), 32.0, 29.8, 29.7, 29.6, 29.4, 29.2,
26.2, 22.7 (8C, 8 x CH2), 14.2 (1C, CH3). MS (MALDI-TOF): m/z cal-
culated for C21H41N3O5 + Na
+ [M + Na+]: 438.29. Found: 438.35.
Compound 56. Compound 52 (140 mg, 0.42mmol) was O-propar-
gylated according to general method D. The crude product was puri-
fied by flash chromatography (hexanes:acetone = 7:3) resulting in 56
(48 mg, 31%) as a slight yellow syrup. 1H NMR (360 MHz, CDCl3):
δ 7.73 (s, 1H, CH=C), 4.61 (s, 2H, OCH2), 4.53 (t, J = 5.1Hz, 2H),
4.18 (d, J = 2.3Hz, 2H), 3.86 (t, J = 5.1Hz, 2H), 3.71–3.57 (m, 12H,
6 x OCH2), 3.51 (t, J = 6.7Hz, 2H), 2.43 (t, J = 2.3Hz, 1H), 1.57 (dt,
J = 14.6, 6.7Hz, 2H), 1.41–1.31 (m, 2H), 0.90 (t, J = 7.4Hz, 3H, CH3).
13C NMR (91 MHz, CDCl3): δ 145.4 (1C, C=CH), 123.7 (1C, C=CH),
74.6 (1C, CH), 70.7, 70.6, 70.5, 69.6, 64.3 (9C, 9 x OCH2), 58.5 (1C,
OCH2C≡CH), 50.3 (1C, NCH2), 31.8, 19.4 (2C, 2x CH2), 14.0 (1C,
CH3). MS (ESI): m/z calculated for C18H31N3O5 + Na
+ [M + Na+]:
392.216. Found: 392.216.
Compound 57. Compound 53 (140 mg, 0.39mmol) was O-propar-
gylated according to general method D. The crude product was puri-
fied by flash chromatography (hexanes:acetone = 7:3) resulting in 57
(60 mg, 39%) as a yellowish syrup. 1H NMR (360 MHz, CDCl3): δ
7.73 (s, 1H, C=CH), 4.61 (s, 2H, OCH2), 4.54 (t, J = 5.1Hz, 2H),
4.19 (d, J = 2.3Hz, 2H), 3.88 (t, J = 5.1Hz, 2H), 3.73–3.59 (m, 12H,
6 x OCH2), 3.51 (t, J = 6.7Hz, 2H), 2.44 (t, J = 2.4Hz, 1H), 1.59 (p,
J = 6.9Hz, 2H), 1.40–1.21 (m, 6H, 3 x CH2), 0.88 (t, J = 6.7Hz, 3H,
CH3).
13C NMR (91 MHz, CDCl3): δ 145.3 (1C, C=CH), 123.5 (1C,
C=CH), 74.6 (1C, CH), 70.8, 70.6, 70.5, 70.4, 69.5, 64.3 (9C, 9 x
OCH2), 58.4 (1C, OCH2C≡CH), 50.3 (1C, NCH2), 31.7, 29.7, 25.8,
22.6 (4C, 4 x CH2), 14.1 (1C, CH3). MS (ESI): m/z calculated for
C20H35N3O5 + Na
+ [M + Na+]: 420.247. Found: 420.249.
Compound 58. Compound 54 (150 mg, 0.39mmol) was O-propar-
gylated according to general method D. The crude product was pu-
rified by flash chromatography (hexanes:acetone = 75:25) resulting in
58 (60 mg, 36%) as a yellow syrup. 1H NMR (360 MHz, CDCl3): δ
7.74 (s, 1H, C=CH), 4.61 (s, 2H, OCH2), 4.54 (t, J = 5.1Hz, 2H),
4.19 (d, J = 2.4Hz, 2H), 3.92–3.84 (m, 2H), 3.73–3.57 (m, 12H, 6 x
OCH2), 3.51 (t, J = 6.7Hz, 2H), 2.44 (t, J = 2.3Hz, 1H, C≡CH), 1.59
(dt, J = 14.4, 6.8Hz, 2H), 1.38–1.21 (m, 10H), 0.88 (t, J = 6.8Hz, 3H,
CH3).
13C NMR (91 MHz, CDCl3): δ 123.6 (1C, C=CH), 74.6 (CH),
70.8, 70.6, 70.5, 70.4, 69.5, 69.2, 64.3 (9C, 9 x OCH2), 58.4 (1C,
OCH2C≡CH), 50.3 (1C, NCH2), 31.8, 29.7, 29.5, 29.3, 26.2, 22.7
(6C, 6 x CH2), 14.1 (1C, CH3). MS (MALDI-TOF): m/z calculated for
C22H39N3O5 + Na
+ [M + Na+]: 448.28. Found: 448.30.
Compound 59. Compound 55 (300 mg, 0.72mmol) was O-propar-
gylated according to general method D. The crude product was pu-
rified by flash chromatography (hexanes:acetone = 7:3) resulting in
59 (284 mg, 87%) as a yellow syrup. 1H NMR (360 MHz, CDCl3):
δ 7.73 (s, 1H, C=CH), 4.62 (s, 2H, OCH2), 4.54 (t, J = 5.1Hz, 2H),
4.20 (d, J = 2.4Hz, 2H), 3.94–3.82 (m, 2H),
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3.78–3.57 (m, 12H, 6 x OCH2), 3.51 (t, J = 6.7Hz, 2H), 2.44 (t,
J = 2.4Hz, 1H, C≡CH), 1.59 (p, J = 6.6Hz, 2H), 1.26 (s, 14H), 0.88
(t, J = 6.7Hz, 3H, CH3).
13C NMR (91 MHz, CDCl3): δ 145.4 (1C,
C=CH), 123.5 (1C, C=CH), 70.9, 70.6, 70.5, 69.6, 69.2, 64.4 (9C, 9
x OCH2), 58.5 (1C, OCH2C≡CH), 50.3 (1C, NCH2), 32.0, 29.7, 29.4,
26.2, 22.8 (8C, 8 x CH2), 14.2 (1C, CH3). MS (MALDI-TOF): m/z cal-
culated for C24H43N3O5 + Na
+ [M + Na+]: 476.31. Found: 476.30.
Compound 60. Azido teicoplanin pseudoaglycon 25 (86mg,
0.06mmol) and propargyl ether 56 (37 mg, 0.10mmol) were allowed
to react according to general method C. The crude product was puri-
fied by flash chromatography (acetonitrile:water = 9:1) resulting in 60
(28 mg, 26%) as a white powder. NMR data can be found in Table
S4. MS (MALDI-TOF): m/z calculated for C84H87Cl2N13O28 + Na
+
[M + Na+]: 1818.51. Found: 1818.4.
Compound 61. Azido teicoplanin pseudoaglycon 25 (86mg,
0.06mmol) and propargyl ether 57 (40 mg, 0.10mmol) were allowed
to react according to general method C. The crude product was puri-
fied by flash chromatography (acetonitrile:water = 9:1) resulting in 61
(39 mg, 36%) as a white powder. NMR data can be found in Table
S4. MS (MALDI-TOF): m/z calculated for C86H91Cl2N13O28 + Na
+
[M + Na+]: 1846.54. Found: 1846.6.
Compound 62. Azido teicoplanin pseudoaglycon 25 (86mg,
0.06mmol) and propargyl ether 58 (43 mg, 0.1mmol) were allowed
to react according to general method C. The crude product was puri-
fied by flash chromatography (acetonitrile:water = 9:1) resulting in 62
(22 mg, 20%) as a white powder. NMR data can be found in Table
S4. MS (MALDI-TOF): m/z calculated for C88H95Cl2N13O28 + Na
+
[M + Na+]: 1874.57. Found: 1874.6.
Compound 63. Compound 25 (100 mg, 0.07mmol) azide was cou-
pled with propargyl ether 59 (41 mg, 0.09mmol) according to gen-
eral method C. The crude product was purified by flash chromatog-
raphy (toluene:MeOH = 1:1 + 1%v/v AcOH) resulting in 63 (35mg,
27%). NMR data can be found in Table S4. MS (MALDI-TOF): m/
z calculated for C90H99Cl2N13O28 + Na
+ [M + Na+]: 1902.60. Found:
1902.60.
Compound 72. Teicoplanin pseudoaglycon 11 (100mg,
0.071mmol) and p-toluenesulfonyl chloride 64 (18 mg, 0.13mmol)
were allowed to react under the conditions described in general
method E. The crude product was purified by flash chromatogra-
phy to give 72 (59 mg, 54%) as a white powder. NMR data can
be found in Table S5. MS (MALDI-TOF): m/z calculated for
C73H64Cl2N8O25S + Na
+ [M + Na+]: 1577.30. Found: 1577.4.
Compound 73. Teicoplanin pseudoaglycon (140 mg, 0.1mmol)
and benzenesulfonyl chloride 65 (18μL, 0.14mmol) were allowed to
react under the conditions described in general method E. The crude
product was purified by flash chromatography to give 73 (82mg,
53%) as a white powder. NMR data can be found in Table S5. MS
(MALDI-TOF): m/z calculated for C72H62Cl2N8O25S + Na
+
[M + Na+]: 1563.28. Found: 1563.6.
Compound 74. Teicoplanin pseudoaglycon (140 mg, 0.1mmol)
and p-acetamidobenzenesulfonyl chloride 66 (33 mg, 0.14mmol) were
allowed to react under the conditions described in general method E.
The crude product was purified by flash chromatography to give 74
(78 mg, 49%) as a white powder. NMR data can be found in Table
S5. MS (MALDI-TOF): m/z calculated for C74H65Cl2N9O26S + Na
+
[M + Na+]: 1620.30. Found: 1620.7.
Compound 75. Teicoplanin pseudoaglycon (140 mg, 0.1mmol)
and biphenylsulfonyl chloride 67 (35mg, 0.14mmol) were allowed to
react under the conditions described in general method E. The crude
product was purified by flash chromatography to give 75 (73mg,
46%) as a white powder. NMR data can be found in Table
S5. MS (MALDI-TOF): m/z calculated for C78H66Cl2N8O25S + Na
+
[M + Na+]: 1639.31. Found: 1639.7.
Compound 76. Teicoplanin pseudoaglycon (140 mg, 0.1mmol)
and dansyl chloride 68 (38mg, 0.14mmol) were allowed to react un-
der the conditions described in general method E. The crude prod-
uct was purified by flash chromatography to give 76 (92mg, 56%)
as a yellow powder. NMR data can be found in Table S5. MS
(MALDI-TOF): m/z calculated for C78H69Cl2N9O25S + Na
+
[M + Na+]: 1656.34. Found: 1656.8.
Compound 77. Teicoplanin pseudoaglycon (100 mg, 0.071mmol)
and hexanesulfonyl chloride 69 (16μL, 0.1mmol) were allowed to re-
act under the conditions described in general method E. The crude
product was purified by flash chromatography to give 77 (28mg,
25%) as a white powder. NMR data can be found in Table S5. MS
(MALDI-TOF): m/z calculated for C72H70Cl2N8O25S + Na
+
[M + Na+]: 1571.34. Found: 1571.7.
Compound 78. Teicoplanin pseudoaglycon (100 mg, 0.071mmol)
and octanesulfonyl chloride 70 (20μL, 0.1mmol) were allowed to re-
act under the conditions described in general method E. The crude
product was purified by flash chromatography to give 78 (32mg,
29%) as a white powder. NMR data can be found in Table S5. MS
(MALDI-TOF): m/z calculated for C74H74Cl2N8O25S + Na
+
[M + Na+]: 1599.38. Found: 1599.4.
Compound 79. Teicoplanin pseudoaglycon (100 mg, 0.071mmol)
and dodecanesulfonyl chloride 71 (27 mg, 0.1mmol) were allowed to
react under the conditions described in general method E. The crude
product was purified by flash chromatography to give 79 (36mg,
31%) as a white powder. NMR data can be found in Table S5. MS
(MALDI-TOF): m/z calculated for C78H82Cl2N8O25S + Na
+
[M + Na+]: 1655.44. Found: 1655.9.
4.5. Influenza virus experiments
All details on the CPE reduction assay for influenza virus can be
found in previous publications [16,25]. The virus strains were: A/PR/
8/34 (A/H1N1); A/Virginia/ATCC3/2009 (A/H1N1pdm); A/HK/7/87
(A/H3N2); B/Ned/537/05; and B/HK/5/72. The infection medium
consisted of Ultra-MDCK® medium (Lonza), supplemented with
0.0225% sodium bicarbonate, 2mM L-glutamine and 2μg/mL tosyl
phenylalanyl chloromethyl ketone-treated trypsin. On day 0,
semi-confluent cultures of Madin-Darby canine kidney (MDCK) cells
in 96-well plates were infected with influenza virus at a multiplicity
of infection (MOI) of 0.0004 plaque forming units (PFU) per cell. Af-
ter three days incubation at 35°C, virus-induced CPE and compound
cytotoxicity were scored by microscopy, after which the data were
confirmed by formazan-based MTS cell viability assay (CellTiter 96®
AQueous One Solution Cell Proliferation Assay from Promega). The
antiviral effect was expressed as the compound concentration produc-
ing 50% inhibition of the virus-induced CPE (EC50). Compound cyto-
toxicity was expressed as the compound concentration causing mini-
mal changes in cell morphology (MCC), and 50% cytotoxic concen-
tration based on MTS (CC50).
The plasmids for the lentiviral pseudoparticle assay [described in
full detail elsewhere [16]] were: pCGGagPol (a gift from G. Maertens
[33]); pQCXIP-AcGFP (kind gift from D. Daelemans); and two pCA-
GEN plasmids, i.e. pCAGEN backbone [kindly provided by C. Cepko
(Boston, MA) via Addgene (plasmid No. 11160[34]] into which we
cloned the A/PR/8/34 HA and NA cDNA sequences. The four plas-
mids were transfected into human HEK-293T cells to produce
GFP-expressing lentiviral particles. Two days after transfection, the
supernatant was collected and trypsin was added to activate the in-
fluenza HA0 protein [16] For lentiviral transduction, MDCK cells
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were seeded at 7500cells per well in 96-well plates, and incubated
one day later with lentiviral particles together with test compounds.
After three days incubation, the cells were trypsinized, fixated with
paraformaldehyde, and submitted to flow cytometry for GFP detec-
tion, using a BD FACSCanto II apparatus.
4.6. Coronavirus experiments
Human embryonic lung fibroblast (HEL) 299cells; human lung
carcinoma A549 cells; and human coronavirus (HCoV) 229E were ob-
tained from ATCC. During virus infections, the medium contained 2%
fetal calf serum. To conduct the CPE reduction assay, confluent HEL
cell cultures in 96-well plates were exposed to HCoV-229E (MOI: 100
CCID50 per well) together with the test compounds. After 5 days incu-
bation at 35°C, microscopy was performed to determine the EC50 and
MCC values (same definition as above).
To perform the qRT-PCR-based coronavirus yield assay, the ma-
terials were: HCoV-229E nucleoprotein-derived forward primer
(5′-TTAGAGAGCGTGTTGAAGGTG-3′); reverse primer
(5′-GTTCTGAATTCTTGCGCCTAAC-3′); probe
(5′-6-FAM-TCTGGGTTG/ZEN/CTGTTGATGGTGCTA-IBFQ-3′;
and a standardization plasmid with a 294-bp sequence of the
HCoV-229E N-gene. As reference compound, the HCoV RNA syn-
thesis inhibitor K22[35] (from ChemDiv) was used.
On day 0, confluent A549 cells in 96-well plates were exposed to
the compounds together with HCoV-229E. One hour after infection,
the virus inoculum was removed and the cells were further incubated
at 35°C in the presence of compounds. At day 3 p.i., the supernatants
were frozen at −80°C. Before qRT-PCR, virions were lysed by treat-
ing 2μl sample with 10μl resuspension buffer and 1μl lysis enhancer
(CellsDirect One-Step qRT-PCR kit; Invitrogen), and 10min incuba-
tion at 75°C. Next, quantification of CoV genome copies was per-
formed by one-step qRT-PCR. The program was run on an Applied
Biosystems 7500 Fast instrument and consisted of 15min at 50°C;
2min at 95°C; and 40 cycles of 15s at 95°C followed by 45s at 60°C.
The EC99 and EC90 values were calculated by interpolation and de-
fined as the compound concentration producing respectively a 2-log10
and 1-log10 reduction in viral RNA copy number, as compared to the
virus control receiving no compound. To monitor compound cytotox-
icity, microscopy was done on mock-infected cells incubated with the
compounds for three days; the MCC value was defined as above.
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